Wolters Kluwer First-Quarter 2025 Trading
Update
Alphen aan den Rijn, May 7, 2025 – Wolters Kluwer, a global
leader in professional information solutions, software and
services, today releases its first-quarter 2025 trading update.
Highlights
- Full-year 2025 guidance reiterated.
- First-quarter revenues up 6% in constant currencies and up 5%
organically.
- Recurring revenues (83% of total) up 7% organically;
non-recurring revenues down 2% organically.
- Expert solutions revenues (59%) grew 6% organically.
- Cloud software revenues (21%) grew 14% organically.
- First-quarter adjusted operating profit increased 11% at
constant currencies.
- First-quarter adjusted free cash flow increased 5% in constant
currencies.
- Rolling 12-months’-net-debt-to-EBITDA was 1.7x as of March 31,
2025.
- 2025 share buyback: €286 million of intended up to €1 billion
buyback completed as of May 5.
Nancy McKinstry, CEO and Chair of the Executive Board,
commented: “We’ve had a solid start to the year, in line with our
expectations, with sustained growth in recurring revenues and good
margin improvement. We continue to invest in delivering AI-powered,
cloud-based expert solutions that support our customers critical
decision-making and help them improve outcomes and productivity.
Our business model and the vital role our solutions play in
customer workflows even in times of uncertainty gives me confidence
in reiterating our full year guidance.”
First-quarter 2025 developments
First-quarter revenues increased 8% in reporting currencies,
reflecting organic growth of 5% (1Q 2024: 6%), a favorable effect
from currency (1Q 2025 average EUR/USD rate was €/$1.05 versus
€/$1.09 in 1Q 2024), and a small net positive effect from
acquisitions and divestitures. The absence in the first quarter of
the extra leap year day had a slightly negative effect on organic
growth. Recurring revenues (83% of revenues), which include
subscriptions and other repeating revenue streams, sustained 7%
organic growth (1Q 2024: 7%). Non-recurring revenues declined by 2%
organically (1Q 2024: 1% organic growth). Within non-recurring
revenues, Financial & Corporate Compliance transactional
revenues recorded 4% organic growth (1Q 2024: 1% pro forma1) while
Legal & Regulatory transactional revenues (ELM Solutions) grew
6% organically (1Q 2024: 11%). Non-recurring software licenses,
implementation services fees, and other non-recurring revenues
declined 6% organically (1Q 2024: 1% organic growth).
Health revenues increased 3% in constant currencies and 4%
organically, as expected, against a challenging comparable (1Q
2024: 7%). Clinical Solutions recorded 5% organic growth (1Q 2024:
9%), mainly reflecting the leap year effect, timing of renewals,
and product discontinuations. In clinical decision support, we
continued the commercial roll-out of AI-powered UpToDate
Enterprise. We announced partnerships with the leading ambient AI
players to seamlessly integrate clinical note-taking capabilities
with UpToDate, creating additional value for customers. In
Learning, Research & Practice, organic growth slowed to 2%, as
expected, against a strong prior period (1Q 2024: 5%) which
had benefitted from full-scale distribution of the New England
Journal of Medicine (NEJM) and the launch of the NEJM AI journal in
December 2023. Print book and print journal revenues trends
reversed to historic rates of decline.
Tax & Accounting revenues increased 8% in constant
currencies and 5% organically, as expected, against a challenging
comparable (1Q 2024: 8%). Recurring revenues grew 7%
organically (1Q 2024: 7%). In North America, organic growth slowed
to 5% (1Q 2024: 8%) due to declines in outsourced professional
services (Xpitax), efiling fees, and print books, all of which had
strong growth in the first quarter of 2024. Recurring cloud
software subscriptions (CCH Axcess suite) grew 19% organically (1Q
2024: 20%). AI-driven tax research (CCH AnswerConnect) was
integrated into the workflow of our Canadian cloud software
platform (CCH iFirm). Our European Tax & Accounting group
delivered 7% organic growth (1Q 2024: 8%) driven by 17% organic
growth in cloud software subscriptions (1Q 2024: 16%). Further
progress was made on integrating the software assets acquired from
the Isabel Group in 2024. Asia Pacific & Rest of World saw
modest organic decline (1Q 2024: 2% organic growth) due to weakness
in China.
Financial & Corporate Compliance revenues grew 4% in
constant currencies and 3% organically (1Q 2024: 4% pro
forma1). Legal Services grew 6% organically (1Q 2024: 4%), driven
by growth in recurring service subscriptions and 6% growth in
transactional revenues (1Q 2024: 0%). In Financial Services,
organic growth slowed to 0% (1Q 2024: 4% pro forma), due to slower
growth in recurring revenues and a decline in Financial Services
transactional revenues amidst stagnant mortgage and commercial
lending markets.
Legal & Regulatory revenues grew 7% in constant currencies
and 7% organically (1Q 2024: 5%). Information Solutions saw 7%
organic growth (1Q 2024: 4%), driven by 8% organic growth in
digital subscriptions and favorable timing of recurring print
revenues. We continued the roll out of GenAI-powered virtual
assistants in the U.S. (VitalLaw) and Benelux (InView) while
preparing for launch in Italy (OneLegale). Legal & Regulatory
Software revenues grew 5% organically (1Q 2024: 6%), with improved
trends in practice management software (Kleos and Legisway) in
Europe offset by slower organic growth at ELM Solutions in the
U.S.
Corporate Performance & ESG revenues increased 10% in
constant currencies and 10% organically (1Q 2024: 8% pro
forma1). Our EHS & ESG2 solutions (Enablon) delivered 12%
organic growth (1Q 2024: 8%), driven by double-digit organic growth
in recurring cloud subscriptions as well as higher on-premise
license fees in the quarter. In Corporate Performance Management
(CPM), the CCH Tagetik CPM platform delivered 13% organic growth
(1Q 2024: 13%), reflecting 19% growth in recurring cloud
subscription revenues partly offset by a decline in on-premise
licenses. Our Corporate Tax and Audit & Assurance units
recorded single-digit organic growth. The division increased
investment to further advance our platforms’ innovative AI
capabilities.
Cash flow and net debt
First quarter 2025 cash conversion increased modestly compared
to first quarter 2024. Adjusted free cash flow increased 5% in
constant currencies, as higher adjusted operating profit was, as
expected, partly offset by increased net financing costs. A total
of €202 million in cash was deployed towards share repurchases
in the first quarter. Net acquisition spending was €387 million,
primarily related to the acquisition of Registered Agent Solutions,
Inc. (RASi) on March 13, 2025.
Net debt was €3,347 million as of March 31, 2025, up from €3,135
million at December 31, 2024. Net-debt-to-EBITDA, based on rolling
twelve-months EBITDA, was 1.7x at the end of March 2025, a slight
increase compared to 1.6x at year-end 2024. On March 20, 2025, we
issued a new €500 million Eurobond with a 7-year term and 3.375%
annual coupon.
Shares outstanding, share buybacks, and dividends
As of March 31, 2025, the number of issued ordinary shares
outstanding (excluding 5.1 million shares held in treasury) was
233.4 million. In the year to date, through May 5, 2025, we have
repurchased 1.9 million ordinary shares for a total consideration
of €286 million (average share price €154.05). This includes a
block trade of €32 million executed on February 27, 2025, to offset
the dilution caused by our incentive share issuance. For the period
starting on May 8, 2025, up to and including July 28, 2025, we have
engaged third parties to execute approximately €350 million in
share buybacks on our behalf, within the limits of relevant laws
and regulations (in particular Regulation (EU) 596/2014) and
Wolters Kluwer’s Articles of Association.
At the Annual General Meeting to be held on May 15, 2025,
shareholders will be asked to approve a total dividend of €2.33
over financial year 2024, an increase of 12% compared to the 2023
dividend. If approved, the final dividend of €1.50 per share will
be paid to shareholders on June 11, 2025 (ADRs: June 18, 2025). The
interim dividend for 2025 will be set at 40% of the 2024 total
dividend.
Sustainability developments
In 2025, we continued to support a wide range of programs
designed to support employee engagement, inclusion, belonging, and
general well-being, with particular emphasis on initiatives that
enhance skills development and strengthen workplace connections for
all employees. Our global real estate team continued executing on
plans to achieve a further reduction in our office footprint and
scope 1 and 2 GHG emissions, while improving workspaces. In April
2025, our long-term targets were validated by the SBTi3 to reach
net-zero greenhouse gas emissions across the value chain by
2050.
Full-Year 2025 Outlook
We reiterate our guidance for the full year as provided in the
table below. We continue to expect full-year 2025 organic growth to
be in line with prior year (FY 2024: 6%). First half organic growth
is expected to be slightly slower due to challenging comparables in
Health and Tax & Accounting. The adjusted operating profit
margin is expected to see improvement in 2025, led by Health and
Corporate Performance & ESG.
Full-Year 2025 Outlook |
Performance indicators |
2025 Guidance |
2024 Actual |
Adjusted operating profit margin* |
27.1%-27.5% |
27.1% |
Adjusted free
cash flow** |
€1,250-€1,300 million |
€1,276 million |
ROIC* |
18%-19% |
18.1% |
Diluted adjusted EPS growth** |
Mid-single-digit growth |
11% |
*Guidance for adjusted operating profit margin and ROIC is in
reporting currency and assumes an average EUR/USD rate in 2025 of
€/$1.07. **Guidance for adjusted free cash flow and diluted
adjusted EPS is in constant currencies (€/$ 1.08). Guidance
reflects share repurchases of €1 billion in 2025. |
In 2024, Wolters Kluwer generated over 60% of its revenues and
adjusted operating profit in North America. As a rule of thumb,
based on our 2024 currency profile, each 1 U.S. cent move in the
average €/$ exchange rate for the year causes an opposite change of
approximately 4.5 euro cents in diluted adjusted EPS. If current
exchange rates persist, the U.S. dollar rate will have a negative
effect on results reported in euros for the remainder of this
year.
Restructuring costs are included in adjusted operating profit.
We expect 2025 restructuring costs to be in the range of €5-15
million (FY 2024: €28 million). Following the acquisition of RASi
and the recent Eurobond issue, we now expect adjusted net financing
costs4 in constant currencies to increase to approximately €85-90
million. The benchmark tax rate on adjusted pre-tax profits is
expected to rise within the range of 23.0%-24.0% (FY 2024: 23.1%).
Capital expenditures are expected to be in the range of 5.0%-6.0%
of total revenues (FY 2024: 5.3%). We expect the full-year 2025
cash conversion ratio to be within 95%-100% (FY 2024: 102%), due to
higher capital expenditures and lower working capital inflows.
Our guidance assumes no additional significant change to the
scope of operations. We may make further acquisitions or disposals
which can be dilutive to margins, earnings, and ROIC in the near
term.
2025 outlook by division
Our guidance for 2025 organic revenue growth by division is
based on a pro forma1 view reflecting the transfer of our Finance,
Risk & Reporting (FRR) unit.
Health: we continue to expect full-year 2025 organic growth to
be in line with or slightly below prior year (FY 2024: 6%) with the
first half facing a challenging comparable.
Tax & Accounting: we continue to expect full-year 2025
organic growth to be in line with prior year (FY 2024: 7%), with
the first half facing a more challenging comparable.
Financial & Corporate Compliance: we continue to expect
full-year 2025 organic growth to be slightly below prior year
(FY 2024: 5% pro forma1), partly due to the suspension of
the CTA.
Legal Regulatory: we continue to expect full-year 2025 organic
growth to be in line with prior year (FY 2024: 5%).
Corporate Performance & ESG: we continue to expect full-year
2025 organic growth to be above prior year (FY 2024:
6% pro forma1) reflecting higher growth for the CCH Tagetik
CPM platform. Organic growth is expected to be more muted in the
second quarter before picking up in the second half of 2025.
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in information
solutions, software, and services for professionals in healthcare;
tax and accounting; financial and corporate compliance; legal and
regulatory; corporate performance and ESG. We help our customers
make critical decisions every day by providing expert solutions
that combine deep domain knowledge with technology and
services.
Wolters Kluwer reported 2024 annual revenues of €5.9 billion.
The group serves customers in over 180 countries, maintains
operations in over 40 countries, and employs approximately 21,900
people worldwide. The company is headquartered in Alphen aan den
Rijn, the Netherlands.
Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and
are included in the AEX and Euronext 100 indices. Wolters Kluwer
has a sponsored Level 1 American Depositary Receipt (ADR) program.
The ADRs are traded on the over-the-counter market in the U.S.
(WTKWY).
For more information, visit www.wolterskluwer.com, follow us on
LinkedIn, Facebook, YouTube, and Instagram.
Financial CalendarMay 15,
2025 Annual
General Meeting of ShareholdersMay 19,
2025 Ex-dividend
date: 2024 final dividend ordinary sharesMay 20,
2025 Record
date: 2024 final dividendJune 11,
2025 Payment
date: 2024 final dividend ordinary sharesJune 18,
2025 Payment
date: 2024 final dividend ADRsJuly 30,
2025 Half-Year
2025 ResultsAugust 26,
2025 Ex-dividend
date: 2025 interim dividend ordinary sharesAugust 27,
2025 Record
date: 2025 interim dividendSeptember 18,
2025 Payment date:
2025 interim dividendSeptember 25,
2025 Payment date:
2025 interim dividend ADRsNovember 5,
2025 Nine-Month 2025
Trading UpdateFebruary 25,
2026 Full-Year 2025
ResultsMarch 11,
2026 Publication
of 2025 Annual Report
Media |
Investors/Analysts |
Stefan Kloet |
Meg Geldens |
Global
Communications |
Investor
Relations |
m +31 (0)612 223
657 |
t +31 (0)172 641
407 |
press@wolterskluwer.com |
ir@wolterskluwer.com |
Forward-looking Statements and Other Important Legal
Information
This report contains forward-looking statements. These
statements may be identified by words such as “expect”, “should”,
“could”, “shall” and similar expressions. Wolters Kluwer cautions
that such forward-looking statements are qualified by certain risks
and uncertainties that could cause actual results and events to
differ materially from what is contemplated by the forward-looking
statements. Factors which could cause actual results to differ from
these forward-looking statements may include, without limitation,
general economic conditions; conditions in the markets in which
Wolters Kluwer is engaged; conditions created by pandemics;
behavior of customers, suppliers, and competitors; technological
developments; the implementation and execution of new ICT systems
or outsourcing; and legal, tax, and regulatory rules affecting
Wolters Kluwer’s businesses, as well as risks related to mergers,
acquisitions, and divestments. In addition, financial risks such as
currency movements, interest rate fluctuations, liquidity, and
credit risks could influence future results. The foregoing list of
factors should not be construed as exhaustive. Wolters Kluwer
disclaims any intention or obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Elements of this press release contain or may contain inside
information about Wolters Kluwer within the meaning of Article 7(1)
of the Market Abuse Regulation (596/2014/EU). Trademarks referenced
are owned by Wolters Kluwer N.V. and its subsidiaries and may be
registered in various countries.
1 All pro forma comparisons in this document reflect the
transfer, as of January 1, 2025, of our Finance, Risk &
Reporting (FRR) unit from the Corporate Performance & ESG
division to the Financial & Corporate Compliance division.2 EHS
& ESG refers to our environmental, health & safety, and
environmental, social & governance solutions.3 SBTi refers to
the Science Based Targets initiative.4 Adjusted net financing costs
include lease interest charges.
- 2025.05.07 Wolters Kluwer First Quarter 2025 Trading
Update
Wolters Kluwers NV (EU:WKL)
Graphique Historique de l'Action
De Mai 2025 à Juin 2025
Wolters Kluwers NV (EU:WKL)
Graphique Historique de l'Action
De Juin 2024 à Juin 2025